Tetra Bio-Pharma (DB:JAM1) - Stock Price, News & Analysis

JAM1 Stock Overview

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology.

About the company

JAM1 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Los beneficios han disminuido en 42.8% al año en los últimos 5 años.

No tiene una capitalización bursátil significativa (€13M)

Tiene unos ingresos inferiores a 1 millón de dólares (CA$0)

Fondos propios negativos

+ 3 more risks

Tetra Bio-Pharma Inc. Competitors

Biofrontera

XTRA:B8F

€22.1m

Apontis Pharma

XTRA:APPH

€65.0m

SynBiotic

DUSE:SBX

€53.6m

MPH Health Care

DB:93M1

€94.2m

Price History & Performance

Summary of all time highs, changes and price drops for Tetra Bio-Pharma
Historical stock prices
Current Share Price	CA$0.013
52 Week High	CA$0.065
52 Week Low	CA$0.0046
Beta	2.26
1 Month Change	0%
3 Month Change	-0.79%
1 Year Change	-59.28%
3 Year Change	-92.13%
5 Year Change	-97.16%
Change since IPO	-72.83%

Recent updates

Shareholder Returns

	JAM1	DE Pharmaceuticals	DE Market
7D	0%	-6.0%	-1.3%
1Y	-59.3%	-31.5%	4.2%

Rentabilidad frente al sector: JAM1 obtuvo unos resultados inferiores a los del sector German Pharmaceuticals , que el año pasado arrojó un rendimiento del -28.2%.

Rentabilidad vs. Mercado: JAM1 obtuvo unos resultados inferiores a los del mercado German, que fue del 5.9% el año pasado.

Price Volatility

Is JAM1's price volatile compared to industry and market?
JAM1 volatility
JAM1 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.7%
10% most volatile stocks in DE Market	9.8%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: JAM1 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de JAM1 en el último año.

About the Company

Founded	Employees	CEO	Website
n/a	33	Guy Chamberland	https://www.tetrabiopharma.com

Tetra Bio-Pharma Inc. Fundamentals Summary

How do Tetra Bio-Pharma's earnings and revenue compare to its market cap?
JAM1 fundamental statistics
Market cap	€8.97m
Earnings (TTM)	-€27.15m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Is JAM1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JAM1 income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$39.02m
Earnings	-CA$39.02m

Last Reported Earnings

Aug 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.076
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-28.1%

How did JAM1 perform over the long term?

See historical performance and comparison

JAM1 Stock Overview

Rewards

Risk Analysis

Tetra Bio-Pharma Inc. Competitors

XTRA:B8F

€22.1m

XTRA:APPH

€65.0m

DUSE:SBX

€53.6m

DB:93M1

€94.2m

Price History & Performance

Recent News & Updates

Tetra Bio-Pharma Inc. Provides Its Shareholders with Another Regulatory Update on the REDUVO™ New Drug Submission

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Tetra Bio-Pharma Inc. Provides Update on Its REDUVO™ New Drug Submission

Tetra Bio-Pharma Inc. and Prepaire Jointly Apply to BARDA for Funding

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 6 million in funding from Alpha Blue Ocean Advisors Ltd

Tetra Bio-Pharma Inc. Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

Recent updates

Tetra Bio-Pharma Inc. Provides Its Shareholders with Another Regulatory Update on the REDUVO™ New Drug Submission

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Tetra Bio-Pharma Inc. Provides Update on Its REDUVO™ New Drug Submission

Tetra Bio-Pharma Inc. and Prepaire Jointly Apply to BARDA for Funding

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 6 million in funding from Alpha Blue Ocean Advisors Ltd

Tetra Bio-Pharma Inc. Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

High number of new and inexperienced directors

Tetra Bio-Pharma Inc. Provides Regulatory Update

Tetra Bio-Pharma Inc. Appoints Leslie Auld as Chief Financial Officer

Tetra Bio-Pharma Receives Ema Orphan Drug Designation for A Novel Topical Therapeutic Containing Cbd

Tetra Bio-Pharma Inc. announced that it expects to receive funding from Cannvalate PTY LTD

High number of new and inexperienced directors

Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 2.129432 million.

Tetra Bio-Pharma Inc. Announces Positive Initial Clinical Data from its Ongoing Phase 2 Clinical Trials (REBORN©1 and PLENITUDE©) of QIXLEEF™ for Cancer Pain

Tetra Bio-Pharma Accelerates REBORN1© Trial

Significant Discovery Reveals New Antiviral Properties of Tetra Bio- Pharma's Innovative Drug ARDS-003

Independent Chairman of the Board William Cheliak has left the company

Health Canada Accepts New Drug Submission for REDUVO™ as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting

Independent Director has left the company

Tetra Bio-Pharma Announces Clinical Advancements

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million.

Tetra Bio-Pharma Inc. Accelerates Plenitude Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

Tetra Bio-Pharma Announces Start of the Reborn1(C) Clinical Trial

Tetra Bio-Pharma Inc. Re-Activates Veterinary Clinical Study in Companion Animals

Tetra Bio-Pharma Inc., Annual General Meeting, May 28, 2021

Tetra Bio-Pharma Provides Status of its New Drug Submission Application in Canada

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 12.54 million.

Tetra Bio-Pharma Inc. (TSX:TBP) entered into a non-binding term sheet to acquire remaining 80% stake in Targeted Pharmaceuticals, LLC for approximately $9.5 million.

New 90-day high: €0.24

Tetra Bio-Pharma Inc. announced that it has received CAD 1.884461 million in funding

Tetra Bio-Pharma Announces FDA Clearance on IND, Allowing U.S. Reborn Clinical Trial to Commence

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 1.894 million in funding

Tetra Bio-Pharma Inc. Completes Investigational New Drug (Ind) -Enabling Toxicology, Clearing the Way for Human Clinical Trials for Its Novel Drug Candidate Ards-003

Tetra Bio-Pharma Inc. Provides Update on Market Potential of ARDS-003

Mondias Natural Products Inc. (TSXV:NHP) completed the acquisition of Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) and certain minority shareholders.

Tetra Bio-Pharma Inc. Unveils Its Commercial Vision on a Robust Chemotherapy Induced Nausea and Vomiting Portfolio

Tetra Bio-Pharma Inc. Enters into A Definitive Agreement with a USA Strategic Partner to Acquire the Canadian Exclusive Rights for Dronabinol Soft Gel Capsules

Tetra Bio-Pharma Inc.(TSXV:TBP) dropped from S&P/TSX Venture Composite Index

Mondias Natural Products Inc. (TSXV:NHP) signed a binding letter of intent to acquire Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) for CAD 1.4 million.